Combinations of DDR1 inhibitors and classical chemotherapeutics reduce tumor burden in orthotopic xenograft and orthotopic pancreatic cancer models (Aguilera et al., 2017). The gene discussed is DDR1; the disease is familial pancreatic carcinoma.